CN1066930C - 用于降低胆固醇的混合饮料组合物 - Google Patents
用于降低胆固醇的混合饮料组合物 Download PDFInfo
- Publication number
- CN1066930C CN1066930C CN94192109A CN94192109A CN1066930C CN 1066930 C CN1066930 C CN 1066930C CN 94192109 A CN94192109 A CN 94192109A CN 94192109 A CN94192109 A CN 94192109A CN 1066930 C CN1066930 C CN 1066930C
- Authority
- CN
- China
- Prior art keywords
- composition
- plantain seed
- acid
- exchange resin
- anion exchange
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 142
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title description 19
- 235000012000 cholesterol Nutrition 0.000 title description 4
- 239000003957 anion exchange resin Substances 0.000 claims abstract description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 229920001268 Cholestyramine Polymers 0.000 claims abstract description 25
- 239000007864 aqueous solution Substances 0.000 claims abstract description 10
- 235000015266 Plantago major Nutrition 0.000 claims description 81
- 235000003805 Musa ABB Group Nutrition 0.000 claims description 80
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 48
- 235000002639 sodium chloride Nutrition 0.000 claims description 34
- 239000002253 acid Substances 0.000 claims description 32
- 235000013361 beverage Nutrition 0.000 claims description 25
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 19
- 235000015165 citric acid Nutrition 0.000 claims description 16
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 15
- 235000011090 malic acid Nutrition 0.000 claims description 15
- 239000001630 malic acid Substances 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 15
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 12
- 239000001354 calcium citrate Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 10
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 10
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 6
- 235000011148 calcium chloride Nutrition 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 5
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 5
- 235000011007 phosphoric acid Nutrition 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 239000011592 zinc chloride Substances 0.000 claims description 5
- 235000005074 zinc chloride Nutrition 0.000 claims description 5
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 5
- 229960001763 zinc sulfate Drugs 0.000 claims description 5
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 5
- 235000011132 calcium sulphate Nutrition 0.000 claims description 4
- 238000009826 distribution Methods 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000004302 potassium sorbate Substances 0.000 claims description 3
- 235000010241 potassium sorbate Nutrition 0.000 claims description 3
- 229940069338 potassium sorbate Drugs 0.000 claims description 3
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 3
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 3
- 235000011151 potassium sulphates Nutrition 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 235000011152 sodium sulphate Nutrition 0.000 claims description 3
- 229960001939 zinc chloride Drugs 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 229960005137 succinic acid Drugs 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 240000008790 Musa x paradisiaca Species 0.000 claims 13
- 150000003014 phosphoric acid esters Chemical class 0.000 claims 1
- 229920002911 Colestipol Polymers 0.000 abstract description 4
- 235000003421 Plantago ovata Nutrition 0.000 abstract description 4
- 241001499741 Plantago arenaria Species 0.000 abstract description 3
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 abstract description 2
- 229960002604 colestipol Drugs 0.000 abstract description 2
- 239000009223 Psyllium Substances 0.000 abstract 3
- 239000010903 husk Substances 0.000 abstract 3
- 229940070687 psyllium Drugs 0.000 abstract 3
- 241001499733 Plantago asiatica Species 0.000 abstract 2
- 244000010922 Plantago major Species 0.000 description 69
- 206010039509 Scab Diseases 0.000 description 34
- 239000000243 solution Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 229920001542 oligosaccharide Polymers 0.000 description 9
- 150000002482 oligosaccharides Chemical class 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 229920002774 Maltodextrin Polymers 0.000 description 6
- 239000005913 Maltodextrin Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940035034 maltodextrin Drugs 0.000 description 6
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 5
- -1 cation salt Chemical class 0.000 description 5
- 238000001879 gelation Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000004040 coloring Methods 0.000 description 4
- 150000002016 disaccharides Chemical class 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 229940073095 questran Drugs 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 230000009967 tasteless effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 235000019605 sweet taste sensations Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 241001127637 Plantago Species 0.000 description 2
- 244000134552 Plantago ovata Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940092124 calcium citrate malate Drugs 0.000 description 2
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 description 2
- 239000001362 calcium malate Substances 0.000 description 2
- 229940016114 calcium malate Drugs 0.000 description 2
- 235000011038 calcium malates Nutrition 0.000 description 2
- 150000001768 cations Chemical group 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 229940097479 colestid Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- GACQNVJDWUAPFY-UHFFFAOYSA-N n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;hydrochloride Chemical group Cl.NCCNCCNCCNCCN GACQNVJDWUAPFY-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 235000012976 tarts Nutrition 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 241000432767 Asparagus setaceus Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical class NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000239204 Plantago lanceolata Species 0.000 description 1
- 235000010503 Plantago lanceolata Nutrition 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 101150039403 ams gene Proteins 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 108010019077 beta-Amylase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940042003 metamucil Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000019533 nutritive sweetener Nutrition 0.000 description 1
- 229940038580 oat bran Drugs 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000011295 pitch Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012260 resinous material Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 229930186851 sennoside Natural products 0.000 description 1
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/238—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seeds, e.g. locust bean gum or guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Dairy Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
含车前子外皮的饮料混合组合物包括车前子外皮、如消胆胺或考来昔泊的阴离子交换树脂、可食用的水溶性盐类。其中所存在的可食用的水溶性盐类数量,当将它分散于水溶液中,足以降低含车前子外皮和阴离子交换树脂的组合物的凝胶速率。
Description
本发明涉及用于降低血清胆固醇浓度的由车前子外皮、一种阴离子交换树脂和可食用的水溶性盐类组成的混合饮料组合物。当将这种组合物分散于水溶液中时,这种盐具有降低饮料混合组合物胶凝速率的优点。较好盐类是中性味觉的,顾客觉察到是“无味型”。
血液胆固醇浓度高与威胁生命的心血管疾病相关。消胆胺(一种阴离子交换树脂)和考来昔泊(colestipol)是用于治疗血胆固醇过多的药物。这类药物被认为是碱性阴离子交换树脂。这类药物明显地与肠道中胆酸结合,从而有助于降低血液胆固醇浓度。可以相信的是这样反过来又增加了胆固醇在肝内的代谢以补充与阴离子交换树脂络合所损失的胆酸。
消胆胺剂量通常是四克,日服一至六次。目前,消胆胺商品名是Questran和QuestranLight(由Bristol-Myers公司生产),以四克单位剂量粉末包装或者粉末状的大体积包装,商品Cholybar(由Parke Davis生产)是一根可咀嚼棒,内含四克消胆胺。[PhysiciansDesk Reference,46th Edition,第710~712页和1705~1706页(1992)]。
考来昔泊通常日服5~30克,一次服用或分成几次。考来昔泊商品名是Colestid(考来昔泊盐酸盐颗粒,由Upjohn公司生产)。考来昔泊以5克单位剂量粉末包装或以粉末状的大体积包装销售。[Physicians Desk Reference,第46版,2328-2329页(1992)]。
最新研究证实,车前子外皮的纤维也能有效地降低人体血清胆固醇浓度。此外,车前子外皮纤维对控制糖尿病患者的血液葡萄糖浓度有效,对通大便和使肠功能正常化有效。已经知道有含车前子外皮的产品(例如,由The Procter&Gamble公司销售的Metamucil)。
含车前子外皮和一种阴离子交换树脂的混合饮料组合物一旦分散于水溶液中,伴随着饮料液粘度增加而变为凝胶。相对于单独的车前子而言,凝胶化速率进一步增加,据认为这是由于阴离子状态的车前子外皮与水溶液中带有多个阳离子基团的阴离子交换树脂发生离子相互作用引起的。为了避免饮用在审美上不能接受的高粘度液体,此种饮料混合悬浮液的消费者必须在相当短时间内(不到两分钟)饮用。过了这段时间后,多半认为该溶液太稠以致于不乐意饮用或者饮用太困难。
控制凝胶化速率的一种可能的方式即采用酸来降低饮料混合液的PH。然而,典型的酸可能给溶液带来太强烈的味道(如酸味或苦味)。尤其是当要求最大限度降低凝胶化速率就涉及到较高的酸浓度。此外,这类酸必须与组合物的味道体系相一致。显然,高酸介质不适合于需要中性或碱性条件的味道体系。而且,除了在某种可被控制环境之外,酸类并不适合于用在无味体系之中。
基于这些理由,继续要求具有降低(缓慢)凝胶速率的含车前子/阴离子交换树脂的饮料混合组合物。本发明业已发现,通过添加足够数量可食用的水溶性盐类可以减慢此种饮料混合组合物在水溶液中的凝胶速率。这种发现是有用的,举例来讲,允许采用较少量的酸或者不用酸(降低或消除饮料组合物的酸性特征),允许更多品种风味体系(包括此种饮料混合组合物“无味”品种),并且进一步降低含有较高酸浓度组合物的凝胶速率。
因此,本发明目的是提供含有车前子和阴离子交换树脂(如消胆胺)并降低在水溶液中凝胶速率和/或改进审美学的外观的改进型饮料混合组合物。还有一个目的是提供无味或非高度酸味体系的此种饮料混合组合物。
本发明的这些目的以及其它目的将通过下述细节变得清楚明了。
本文所用的所有百分数和比例除非特指外均以重量为基础。本专利所用的筛孔大小按照美国标准。
发明提要
本发明涉及关于降低血清胆固醇饮料混合组合物。此种组合物包含:(a)含约10%到约90%车前子外皮;(b)约10%到约90%阴离子交换树脂;(c)约0.1%至约30%可食用的水溶性盐,依据该值可降低饮料混合组合物在水溶液中胶凝速率;和(d)从约0%至约90%其它赋形剂;而且所述组合物是与液体是可混合的,以便形成车前子外皮和阴离子交换树脂的悬浮液。
本发明的详细叙述
本发明饮料混合组合物是以任何方式含有车前子外皮和一种阴离子交换树脂的用于降低血清胆固醇浓度的组合物,适合于与液体混合形成车前子/阴离子交换树脂悬浮液以供口服。较好形式是大包装干粉末或者单位剂量包装形式,这种形式易于混合和分散于液体中。按照本发明的组合物的组份和典型数量在下面详尽地描述。车前子的外皮
本发明所用的车前子外皮系来自于车前子种籽,来自于车前属植物。已知有多种品种,如长叶车前(Plantago lanceolate),黑籽车前(P.rulgelli)和大车前(P.major)。商品车前子外皮包括法国[黑色;印度车前(Plantago indica)]西班牙亚麻籽车前(P.psyllium)和印度(淡黄色;卵叶车前(P.ovata))。本专利较好地使用印度(淡黄色)车前子外皮。而且,合适的车前子至少约85%纯度,更合适的至少约90%纯,最合适的至少约95%纯。
从包覆车前子种籽的外衣得到车前子外皮。典型的方式是将包在种籽的表皮从种籽的其余部分中取出,例如用轻微机械压力方式,接着仅利用种子表皮。最好将种子表皮取出,再用熟知工艺方法消毒。较好的是将具有基本上完整细胞结构的车前子外皮进行消毒,采用环氧乙烷消毒和过热蒸汽消毒法来进行消毒。(按照Leland等于1990年3月27日公开的美国专利U.S Patent No.4,911,889进行,该专利公开内容全文放在本专利中以供参考)。还认为本专利所用的车前子外皮以降低颗粒大小更为优选(按照Leis,Jr等于1992年9月22日刊出的美国专利号5,149,541进行,该专利公开内容以全文放在本专利中以供参考)。
本发明组合物所用的较合适的是“小颗粒尺寸的车前子外皮”。本专利所用的术语“小颗粒尺寸的车前子外皮”是指,在本发明组合物中利用的车前子具有大量小颗粒尺寸车前子外皮,以致于车前子外皮是由超过90%分布的车前子外皮颗粒大小是低于350μm(45目)。更合适的,超过约80%是低于297μm(50目),还要合适的是超过约80%是低于250μm(60目),最合适的至少约80%是低于约177μm(80目)。进一步较好的颗粒大小的分布如下:低于约25%是高于约250μm(60目),并且至少约40%是低于约177μm(80目)。更加好的颗粒大小分布是:低于约10%是高于约250μm(60目),至少约40%是在约177μm(80目)至约74μm(200目)范围内,低于约50%是小于约74μm(200目)。由一位普通本技术熟练工就可以容易地测定颗粒大小和颗粒大小分布,例如采用Alpine实验室气喷筛进行筛选(Natick Mass的Alpine American Corp.销售)。
饮料混合组合物较好地包含从约10%至约90%车前子外皮,更好的是从约20%至90%,最好的是从约25%至75%。
阴离子交换树脂
本专利所用的术语“阴离子交换树脂”是指具有阳离子基团部分的任何树脂类材料,以致于该材料用来治疗高胆固醇血症既安全又有疗效(在合理医学判断范围内有合理的利益/风险比)。本专利所用的较好阴离子交换树脂包括消胆胺、考来昔泊及其混合物。
消胆胺是由接连于苯乙烯-二乙烯苯共聚物的季铵功能团而组成的强碱型阴离子交换树脂。[The Merck Index,第10版,由Mer-ck&Co.出版,No.2182(1983),以全文放入本专利中供参考)。含消胆胺树脂的组合物以粉末型商品提供,商品名Cuemid(Merck,Sharp&Dome)和Questran和QuestranLight(Bristol-Myers的Bristol实验室分部)。消胆胺商品是Duolite Ap-143树脂(Rohm&Haas Co.)。
考来昔泊是二亚乙基三胺和1-氯-2,3-环氧丙烷的不溶性高分子量碱性阴离子交换共聚物,它带有的5个氨基氮中1个被质子化(氯型)。[The Merck Index,第11版,由Merck&Co.出版,No.2472(1989),以全文放入本专利中供参考)。考来昔泊商品以考来昔泊盐酸盐颗粒提供,商品名Colestid(Upjohn)。
本发明组合物中阴离子交换树脂典型包括按本发明药物组合物重量计算的为约10%至90%,较好地从约20%至约90%。按本发明药物组合物重量计,最适合的阴离子交换树脂包括约25%至75%。可食用的水溶性盐类:
本专利所用的术语“可食用的水溶性盐类”指任何盐原料,有机物或者无机物,它溶于水中(按对含车前子/阴离子交换树脂饮料混合组合物的正常使用条件),并且pKa大于5,这对人体摄入是安全的。可食用的水溶性盐类实例包括硫酸镁、氯化钙、硫酸钙、苹果酸柠檬酸钙、氯化钾、氯化钠、硫酸钾、硫酸钠、氯化锌、硫酸锌、山梨酸钾及其上述混合物。较合适盐类是二价阳离子盐类(例如钙、镁、锌),尤其是强无机酸阳离子盐类(例如硫酸镁、硫酸钙、氯化钙、硫酸锌、氯化锌以及上述混合物)。
本专利所用术语“苹果酸柠檬酸钙”指柠檬酸钙和苹果酸钙的混合物或者(较合适)络合物。这种苹果酸柠檬酸钙可包括柠檬酸钙和苹果酸钙的混合物,含柠檬酸和苹果酸配位体的钙络合物,钙盐与柠檬酸和苹果酸的混合物,或者上述结合物。苹果酸柠檬酸钙是高生物利用度钙的来源。本专利所用的苹果酸柠檬酸钙可用粉末,或者在现场制备使用。较好的苹果酸柠檬酸钙的钙∶柠檬酸∶苹果酸的摩尔比约6∶2∶3和4∶2∶3。下述文献叙述制备苹果酸柠檬酸钙方法,以全文列入本专利以供参考:日本专利说明书SHO56-97248,Kawai,1981年8月5日出版;Heckert,美国专利U.S.Patent 4,722,847,1988年2月2日;Fox等,美国专利U.S.Patent 5,186,965,1993年2月16日。
本发明目的就要求必须在有足够数量的可食用的水溶性盐存在下,相对于未加盐的组合物而言,降低饮料混合组合物的凝胶速率。这一点对某些有机酸盐类尤其重要,这种盐类在某种浓度时可对车前子单独悬浮液产生提高凝胶速率的不需要的效应(例如,使溶液增稠,更耐久),但是在某些浓度时使用,按照本发明会产生降低凝胶速率的所希望的优点。
按照本发明要求,采用简单实验易于确定在含车前子/阴离子交换树脂组合物中所存在的盐数量是否符合需要。举例来讲,可将含盐的组合物的粘度增加速率与含相同组分但无可食用水溶性盐的组合物的粘度增加速率作对比。如果添加所用盐的数量降低了凝胶速率,按本发明而言存在足够数量盐类。可用众所周知的测量凝胶速率和溶体粘度的方法和设备,此种测量和测定对本技术熟练者很容易做到。举例来讲,可以采用Brookfield粘度计,下文举例说明。
本发明组合物可包含从约0.1%至约50%可食用的水溶性盐类,较好的从约0.1%至约20%,更好的从约0.5%至约5%(按饮料混合组合物重量计)。其它赋形剂:
本发明组合物中其它赋形剂必须对人体口服是安全的,可由这项技术的一名普通熟练工作者对打算用作产品的饮料混合形式和用途作出恰如其分的选择。含车前子饮料混合产物、制造方法、用作这类产品的其它赋形剂在下述专利中更为详尽描述,例如,Colliopou-los等,1984年7月10日刊出,美国专利号U.S.Patent,4,459,280,Colliopoulos等,1985年10月22日,美国专利号U.S.Patent4,548,806;Powell等,1982年3月23日,美国专利号U.S.Patent4,321,263;Furst等,1989年5月9日,美国专利号U.S.Patent 4,828,842;所有这些专利以全文列入本专利中以供参考。本发明饮料混合组合物包括从约0%至约90%其它赋形剂,较好的从约1%至约60%,更好的从约2%至约50%。
本发明最适合的产品是适合于将干粉混合在液体中,就形成含车前子/阴离子交换树脂的饮料的形式。已经知道此种粉末形式的较合适的其它赋形剂,并且也详尽地叙述过,例如美国专利号U.S.Patent 4,459,280和4,548,806。较好的是由麦芽糊精组成的此类粉末(较好的是无糖)。而且,特别适宜是包括车前子和/或涂覆过的车前子的结成团块的粉末,特别是带有麦芽糊精和/或蔗糖的结成团块物。
已经知道本专利所用的较合适的结成团块的材料。这类材料包括由下述组成的一组中供选择材料:水可分散的水解淀粉低聚糖、单糖、双糖、多葡萄糖(polyglucose)、多麦芽糖(polymaltose)以及上述混合物。本发明组合物较好地包括涂在上述车前子外皮上的0.5%到约20%的结成团块的材料,更好地从约1%到10%,最好从约1%到5%。
淀粉水解或者用酸、酶(如α-淀粉酶、β-淀粉酶或淀粉葡糖苷酶)反应,或者两者一起结合反应,或者两者连续反应。这种水解按照不同途径,取决于采用酸还是酶。结果是寡糖混合物,依据寡糖的不同性质可进行分离。所得到的分离出来的水可分散(最好是可溶性)水解淀粉寡糖是按寡糖的所含的还原糖进行分类,例如单糖或双糖(如葡萄糖或果糖)。在这种特定水解淀粉寡糖中还原糖的百分含量是按重量/重量为基础以葡萄糖当量(或D.E.)来测量。D.E.从0到20的水解淀粉寡糖被称为麦芽糊精。这种固体麦芽糊精具有低至中等甜味,低至中等吸湿性,在水和乙醇中溶解,而且具有还原的棕色着色剂。D.E.值超过约20,这种水解淀粉寡糖被称为糖浆固体。这种糖浆固体是可溶性的,但具有较明显甜味,更吸湿。D.E.值超过30,不太希望采用糖浆固体于本专利中。因此,一种较合适的水可分散的水解淀粉寡糖的D.E.从约0到约30。较合适的麦芽糊精的D.E.从约5至约20,更合适的约10(即还原糖含量比例是寡糖的10%W/W)。
单糖一般是已糖或戊糖的醛-醇或酮-醇,并且具有甜味。单糖易溶解于水中,形成结晶固体。双糖的范例是在水解时产生两个单糖的糖类。双糖的实例是乳糖、蔗糖和麦芽糖。
本发明的较好的组合物包括一种可食用的酸,作为任意选择的其它赋形剂的一部分或者全部。本专利所用的术语“可食用的酸”是指任何水溶性的酸性物质,它的pKa值低于5,较好的是从约2至约5范围,这种物质为人体摄入时是安全的。可食用的酸实例包括(但并不限于此)柠檬酸、抗坏血酸、苹果酸、琥珀酸、酒石酸、磷酸、磷酸单钾、以及上述混合物。较好的酸是抗坏血酸、磷酸、苹果酸和柠檬酸,以柠檬酸最合适。
所述其它赋形剂包含按组合物重量计0.1%至25%,较好是低于2%可食用的酸。作为一个例子,其它赋形剂可以包括0.1%至10%,较好是低于1%选自柠檬酸、磷酸及其混合物的可食用的酸。
本发明组合物典型地包括从约0.1%至约25%可食用的酸,较好的从约0.1%至约10%,更好的从约0.1%至5%。而且,较好的是含不到2%可食用的酸的组合物,更合适的是不超过1%可食用的酸,最合适的是低于约0.5%可食用的酸。
本发明较好组合物是有一些或者全部可食用的酸被涂在车前子的外皮上,更合适的是车前子外皮被凝结成团块。欧洲专利应用号412,604(1991年2月13日刊)叙述了凝结成团块的车前子外皮,该专利全文内容列入本专利供参考。采用设备可实现车前子外皮的较合适的单层涂层(本专利参照单程流化粉末润湿装置),该设备最好如下操作:让含车前子的原料的干混合物滴落通过由园筒壁形成的高湍流环形区,该区是由圆筒壁和具有不同节距所接连叶片的旋转轴所形成。一种可食用的含酸溶液最好被喷入这环区,与干燥的含车前子的混合物接触。所得到的涂过的(较好的是被凝结的)车前子外皮滴落至流化床干燥器,在干燥器中除去所添加的溶剂。该设备的实例是Bepex Turboflex Model No.TFX-4(由明尼苏达州Min-neapolis的Bepex Corporation销售),该设备有六平方呎床的振动流化床干燥器(由新泽西州Washington的Witte Corporation销售)。
含车前子的混合物最好包含从约25%至约100%车前子。含车前子混合物的任意选择组分包括(但并不限于)可食用的酸、增甜剂(最好是低热量增甜剂,包括下述增甜剂但不限于这些增甜剂:天冬酰苯丙氨酸甲酯(营养性甜味剂)、糖精、环己烷氨基磺酸盐、双氧噁噻嗪(合成甜味剂)以及上述混合剂)、着色剂、凝结材料(尤其是麦芽糊精)、食用纤维如糠类(例如,麦麸;燕麦麸;稻糠)和/或药剂(如非甾族类抗炎剂;阿斯匹林;番泻叶苷)。在含车前子的混合物中也可包含某些或者全部的可食用的水溶性盐和/或阴离子交换树脂。如本专利前述,较好的是含车前子的混合物是干燥的,但可利用适当溶剂(如乙醇和/或水),但要求小心,尤其当用水时更要谨慎,不要使车前子引起相当大的水合作用和溶胀,因为这可预料到对于车前子外皮与水或其它流体相作用时的速率产生不利效果。
较好地随着含一种或多种可食用酸的溶液混合物被喷至含车前子的混合物上时,同时也包括一些或全部的可食用的水溶性盐类。可以选择一种液体(如,醇和/或水)作为涂到车前子外皮上合适材料,从而制备出该混合物。然而,较好的是利用水。也是较好地将该溶液混合物喷到含车前子的干燥混合物上。较好的是,当采用喷雾技术时,溶液混合物是含从约1%至约50%的可食用的水溶性盐(较好的是从约10%至约25%)以及从0%到约50%(较好的从约1%至约20%)可食用酸的水溶液。也可随意地反复涂覆和干燥步骤,因此在车前子外皮上构成一涂层,该层包含数层薄的材料。除此以外,溶液混合物还可存在其它可选择的材料,如着色剂、药剂以及上述混合物。
按照本发明制备组合物的其它方法包括干掺和组分以及将车前子外皮进行多层涂覆的其它手段。其它手段可利用例如采用流化床凝结成大块的设备来实现,这种设备是Fluid Air,Inc的Model0300 Granulator-Dryer。治疗方法
本专利治疗法包括需要降低血液胆固醇浓度的人体或较低等动物患者口服。一种按照本发明的含车前子/阴离子交换树脂组合物的安全并有效数量的水质悬浮液。本专利所用的术语“安全和有效数量”是指,车前子纤维/阴离子交换树脂组合物的数量高至足于明显肯定性减轻被治疗的高胆固醇血情况,但按照严格医学判断范围内低至可以避免发生严重付效应的程度(在一合理的利益/风险比)。这种安全和有效数量随被治疗患者的年龄和身体条件而变,还随疾病的本质、治疗的持续时间、同时治疗的本性以及在主治医师知识和经验范围之内等因素而变。然而,需求此种治疗的患者典型地接受每日4g到约24g阴离子交换树脂和1g至30g车前子外皮。
下述例子进一步叙述和说明本发明范围内的具体例子。这些实施例仅起说明的目的,并不构成本发明的限制性,因为可以作出多种方式的变动但并未脱离开这种精神和范畴。
实施例1
组 分 配方中%
车前子Mucilloida) 40.60
消胆胺树脂b) 45.10
柠檬酸 7.30
桔子味 3.40
柠檬酸钠 1.70
天冬酰苯丙氨酸甲脂 0.62
氯化钙 1.10
着色剂 0.09
a)车前子外皮的颗粒大小约100%通过80目。
b)由Rohm和Haas供应。
用干法掺和这些组分以制成这种组合物。需求降低胆固醇的人员每日两次服用8.86g这种组合物,悬浮于8盎司水中,4g的消胆胺和3.6g车前子对降低血清胆固醇是有效的。
实施例2
为了评价添加各种数量可食用的水溶性盐类的数值,通过下述对比试验进行评价悬浮于柠檬酸溶液中的小颗粒尺寸车前子外皮和消胆胺的粘度增加速度。采用下述组分制备悬浮液:
重量 %d)
悬浮液# 1、 2、 3、 4、 5
车前子a) 45.6 44.8 44.3 44.8 44.3
消胆胺b) 53.3 52.5 51.9 52.5 51.09
柠檬酸c) 1.11 1.09 1.08 1.09 1.08
CaCl2·2H2O - - - 1.64 2.70
MgSO4·7H2O - 1.64 2.70 - -
a)约100%小于约80目;每悬浮液中加8.2g。
b)每悬浮液中添加9.6g。
c)柠檬酸;20克1%柠檬酸水溶液(按重量计),先用水稀释得到总重为480克。
d)表中重量%是添加水之前的。
将所有组分的干掺和物(除了柠檬酸预溶解于水中)添加到480克柠檬酸溶液中,在600ml烧杯中搅拌30秒。在每种悬浮液中,添加的车前子和消胆胺重量保持恒定(由于CaCl2或MgSO4存在与否,使经过各种悬浮液的消胆胺和车前子的重量%有所改变)。采用Brookfield粘度计测量悬浮液粘度(#RVT型;1号转子;10RPM)。各种时间的悬浮液粘度如下:
悬浮体#: 1 2 3 4 5
时间 粘度(厘泊)
60 412 385 338 360 300
90 497 425 420 420 370
120 587 500 502 505 450
150 667 590 582 590 505
Claims (16)
1.一种含车前子外皮/阴离子交换树脂饮料混合组合物包括:
a)从10%至75%车前子外皮;
b)从10%至75%选自由消胆胺,考来昔泊及其混合物组成的组的阴离子交换树脂;
c)从0.1%至50%可食用的水溶性盐,在这种盐浓度时,可使含车前子/阴离子交换树脂饮料混合组合物在水溶液中的凝胶速率降低;和
d)从0%到60%其它赋形剂;而且其中所述的组合物是与液体可混合的,以便形成车前子外皮和阴离子交换树脂的悬浮液。
2.如权利要求1所述的组合物,其特征在于,可食用的水溶性盐系由下述组成的组中选择:硫酸镁、氯化钙、硫酸钙、苹果酸柠檬酸钙、氯化钾、氯化钠、硫酸钾、硫酸钠、氯化锌、硫酸锌、山梨酸钾及其混合物。
3.如权利要求1所述的组合物,其特征在于,其它赋形剂包括按组合物重量计的0.1%至25%可食用的酸。
4.如权利要求2所述的组合物,其特征在于,其它赋形剂包含按组合物重量计的0.1%至25%可食用的酸。
5.如权利要求4所述的组合物,其特征在于,可食用的酸选自由下述组成的组中:柠檬酸、抗坏血酸、苹果酸、琥珀酸、酒石酸、磷酸、磷酸单钾盐及其混合物。
6.一种含车前子外皮/阴离子交换树脂饮料混合组合物包含:
a)从20%至75%车前子外皮;
b)从20%至75%阴离子交换树脂,选自由消胆胺,考来昔泊及其混合物组成的组;
c)从0.1%至20%可食用的水溶性盐,在这种盐浓度时,可使含车前子/阴离子交换树脂饮料混合组合物在水溶液中的凝胶速率降低;和
d)从1%到50%其它赋形剂;而且其中所述的组合物是与液体可混合的,以便形成车前子外皮和阴离子交换树脂的悬浮液。
7.如权利要求6所述的组合物,其特征在于,可食用水溶性盐由下述组成的组中选择:硫酸镁、氯化钙、硫酸钙、苹果酸柠檬酸钙、氯化钾、氯化钠、硫酸钾、硫酸钠、氯化锌、硫酸锌、山梨酸钾及其混合物。
8.如权利要求6所述的组合物,其特征在于,其它赋形剂包含按组合物重量计的0.1%至10%可食用的酸。
9.如权利要求8所述的组合物,其特征在于,其它赋形剂包括按组合物重量计低于2%的可食用的酸。
10.如权利要求7所述的组合物,其特征在于,其它赋形剂包括0.1%至10%选自柠檬酸、磷酸及其混合物的可食用的酸。
11.如权项要求10所述的组合物,其特征在于,其它赋形剂包含按组合物重量计低于1%可食用的酸。
12.一种含车前子外皮/阴离子交换树脂组合物包含:
a)从约20%至75%小颗粒尺寸车前子外皮,颗粒大小的分布是超过90%的颗粒小于350μm;
b)从20%至75%选自由消胆胺,考来昔泊及其混合物组成的组的阴离子交换树脂;
c)从0.1%至50%可食用的水溶性盐,在这种盐浓度时,可使含车前子/阴离子交换树脂饮料混合组合物在水溶液中的凝胶速率降低;和
d)从1%到50%其它赋形剂;而且其中所述的组合物是与液体可混合的,以便形成车前子外皮和阴离子交换树脂的悬浮液。
13.如权利要求12所述的组合物,其特征在于,小颗粒尺寸车前子外皮分布是超过80%的颗粒小于250μm。
14.如权利要求12所述的组合物,其特征在于,可食用的水溶性盐选自由下述组成的组中:硫酸镁、硫酸钙、氯化钙、硫酸锌、氯化锌及其混合物。
15.如权利要求14所述的组合物,其特征在于,阴离子交换树脂选自由消胆胺、考来昔泊及其混合物组成的组。
16.如权利要求15所述的组合物,其特征在于,其它赋形剂含按组合物重量计低于2%可食用的酸。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/061,926 US5422101A (en) | 1993-05-14 | 1993-05-14 | Cholesterol lowering drink mix compositions |
US08/061,926 | 1993-05-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1124006A CN1124006A (zh) | 1996-06-05 |
CN1066930C true CN1066930C (zh) | 2001-06-13 |
Family
ID=22039048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94192109A Expired - Fee Related CN1066930C (zh) | 1993-05-14 | 1994-04-15 | 用于降低胆固醇的混合饮料组合物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US5422101A (zh) |
EP (1) | EP0697821B1 (zh) |
JP (1) | JPH08510125A (zh) |
CN (1) | CN1066930C (zh) |
AT (1) | ATE173380T1 (zh) |
AU (1) | AU689775B2 (zh) |
BR (1) | BR9406579A (zh) |
CA (1) | CA2162249C (zh) |
DE (1) | DE69414704T2 (zh) |
WO (1) | WO1994026130A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06504281A (ja) * | 1990-12-20 | 1994-05-19 | ザ、プロクター、エンド、ギャンブル、カンパニー | 改良された嗜好性を有するオオバコ及びコレスチラミン組成物 |
US6139850A (en) * | 1994-12-21 | 2000-10-31 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
US7404967B2 (en) * | 1994-12-21 | 2008-07-29 | Cosmederm, Inc. | Topical product formulations containing strontium for reducing skin irritation |
US5958436A (en) * | 1995-12-21 | 1999-09-28 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
US5942550A (en) * | 1996-01-25 | 1999-08-24 | The Procter & Gamble Company | Cholesterol lowering drink mix compositions |
US5612026A (en) * | 1996-01-25 | 1997-03-18 | The Procter & Gamble Company | Cholesterol lowering drink mix compositons |
AUPO763197A0 (en) * | 1997-06-30 | 1997-07-24 | Sigma Pharmaceuticals Pty Ltd | Health supplement |
JP4863589B2 (ja) * | 2001-09-28 | 2012-01-25 | ロート製薬株式会社 | 水性組成物 |
US7276115B1 (en) * | 2003-07-17 | 2007-10-02 | Cathey Timothy D | Conformable coating |
US20060039973A1 (en) * | 2004-08-19 | 2006-02-23 | Mary Aldritt | Effervescent composition including water soluble dietary fiber |
US11484547B2 (en) | 2018-01-08 | 2022-11-01 | Performance Labs PTE. LTD. | Compositions and methods for cholesterol, glucose and microbiome control |
JP7280850B2 (ja) * | 2020-03-25 | 2023-05-24 | 日清食品ホールディングス株式会社 | 測定方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992011019A1 (en) * | 1990-12-20 | 1992-07-09 | The Procter & Gamble Company | Psyllium and cholestyramine compositions with improved palatability |
WO1993013801A1 (en) * | 1992-01-17 | 1993-07-22 | The Procter & Gamble Company | Treatment for atherosclerosis |
WO1993025095A1 (en) * | 1992-06-12 | 1993-12-23 | The Procter & Gamble Company | Psyllium drink mix compositions |
WO1993025096A1 (en) * | 1992-06-12 | 1993-12-23 | The Procter & Gamble Company | Psyllium drink mix compositions |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US906709A (en) * | 1906-11-02 | 1908-12-15 | Manabran Laxative Biscuit Company | Biscuit. |
US2060336A (en) * | 1933-04-05 | 1936-11-10 | Libby Mcneill & Libby | Composition of matter containing vegetable mucinous extract from plants |
US3148114A (en) * | 1959-11-20 | 1964-09-08 | American Cyanamid Co | Method of reducing cholesterol levels |
US3455714A (en) * | 1964-09-01 | 1969-07-15 | Hercules Inc | Cellulose derivatives of improved dispersibility and process |
GB1566609A (en) * | 1977-03-10 | 1980-05-08 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions containing cholestyramine and alginic acid |
FR2438431A1 (fr) * | 1978-10-09 | 1980-05-09 | Grimberg Georges | Produits speciaux et compositions pharmaceutiques a base de son pour dispersions |
US4341805A (en) * | 1979-09-10 | 1982-07-27 | Miller Brewing Company | High dietary fiber product |
US4511561A (en) * | 1980-01-16 | 1985-04-16 | Dr. Madaus & Co. | Laxative composition comprising psyllium seeds and senna fruits |
US4321263A (en) * | 1980-09-30 | 1982-03-23 | Rowell Laboratories, Inc. | Psyllium compositions |
US4548806A (en) * | 1982-07-23 | 1985-10-22 | G. D. Searle & Co. | Psyllium hydrophilic mucilloid composition |
US4459280A (en) * | 1982-07-23 | 1984-07-10 | G. D. Searle & Co. | Psyllium hydrophilic mucilloid composition |
IN156314B (zh) * | 1982-09-01 | 1985-06-22 | Searle & Co | |
US4551331A (en) * | 1983-06-02 | 1985-11-05 | S. C. Johnson & Son, Inc. | Easily dispersible dietary fiber product and method for producing the same |
USRE32811E (en) * | 1983-06-02 | 1988-12-27 | S. C. Johnson & Son, Inc. | Easily dispersible dietary fiber product and method for producing the same |
US4487866A (en) * | 1983-06-22 | 1984-12-11 | Halliburton Company | Method of improving the dispersibility of water soluble anionic polymers |
US4557938A (en) * | 1983-08-17 | 1985-12-10 | Eugene H. Sander | Product and process for improving the dispersion of a vegetable gum in water |
DK454683D0 (da) * | 1983-10-03 | 1983-10-03 | Mogens Gjerloev | Tarmreguleringsmiddel til behandling af diarre hos dyr samt anvendelse heraf |
DE3479630D1 (en) * | 1983-12-12 | 1989-10-12 | Procter & Gamble | Psyllium mucilloid products |
US4619831A (en) * | 1984-06-04 | 1986-10-28 | Warner-Lambert Company | Dietary fiber composition and process of manufacture |
US4565702A (en) * | 1984-06-04 | 1986-01-21 | Warner-Lambert Company | Dietary fiber food products and method of manufacture |
US4747881A (en) * | 1985-02-05 | 1988-05-31 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
US4639367A (en) * | 1985-03-18 | 1987-01-27 | Product Resources International, Inc. | Aerosol foam |
US4731246A (en) * | 1985-10-31 | 1988-03-15 | Product Resources International, Inc. | Liquid bran drink |
US4737364A (en) * | 1986-02-06 | 1988-04-12 | Kalogris Theodore P | Nutritional dry food concentrate |
US4824672A (en) * | 1986-06-06 | 1989-04-25 | Hauser-Kuhrts, Inc. | Method and composition for reducing serum cholesterol |
US4828842A (en) * | 1986-09-16 | 1989-05-09 | L. Perrigo Company | Water dispersible compound |
US4784861A (en) * | 1986-11-24 | 1988-11-15 | Cca Industries, Inc. | Weight-control formulation |
US4849222A (en) * | 1987-03-24 | 1989-07-18 | The Procter & Gamble Company | Mixtures for treating hypercholesterolemia |
US4812315A (en) * | 1987-05-14 | 1989-03-14 | Tarabishi M Hisham | Diet pills |
FR2616329B3 (fr) * | 1987-06-15 | 1990-06-15 | Chicouri Marcel | Nouvelles compositions laxatives et leur procede d'obtention |
DE3869590D1 (de) * | 1987-12-29 | 1992-04-30 | Procter & Gamble | Mischung zur behandlung von hypercholesterolemie. |
CA1331535C (en) * | 1988-10-03 | 1994-08-23 | Paul Dale Leis Jr. | Psyllium-containing products |
ATE92328T1 (de) * | 1989-08-10 | 1993-08-15 | Procter & Gamble | Essbare saeure enthaltende agglomerierte psyllium- spelze. |
-
1993
- 1993-05-14 US US08/061,926 patent/US5422101A/en not_active Expired - Fee Related
-
1994
- 1994-04-15 JP JP6525438A patent/JPH08510125A/ja active Pending
- 1994-04-15 EP EP94914803A patent/EP0697821B1/en not_active Expired - Lifetime
- 1994-04-15 BR BR9406579A patent/BR9406579A/pt not_active Application Discontinuation
- 1994-04-15 DE DE69414704T patent/DE69414704T2/de not_active Expired - Fee Related
- 1994-04-15 CN CN94192109A patent/CN1066930C/zh not_active Expired - Fee Related
- 1994-04-15 AT AT94914803T patent/ATE173380T1/de not_active IP Right Cessation
- 1994-04-15 AU AU67056/94A patent/AU689775B2/en not_active Ceased
- 1994-04-15 CA CA002162249A patent/CA2162249C/en not_active Expired - Fee Related
- 1994-04-15 WO PCT/US1994/004177 patent/WO1994026130A1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992011019A1 (en) * | 1990-12-20 | 1992-07-09 | The Procter & Gamble Company | Psyllium and cholestyramine compositions with improved palatability |
WO1993013801A1 (en) * | 1992-01-17 | 1993-07-22 | The Procter & Gamble Company | Treatment for atherosclerosis |
WO1993025095A1 (en) * | 1992-06-12 | 1993-12-23 | The Procter & Gamble Company | Psyllium drink mix compositions |
WO1993025096A1 (en) * | 1992-06-12 | 1993-12-23 | The Procter & Gamble Company | Psyllium drink mix compositions |
Also Published As
Publication number | Publication date |
---|---|
EP0697821B1 (en) | 1998-11-18 |
AU6705694A (en) | 1994-12-12 |
ATE173380T1 (de) | 1998-12-15 |
BR9406579A (pt) | 1996-01-30 |
JPH08510125A (ja) | 1996-10-29 |
DE69414704T2 (de) | 1999-06-24 |
EP0697821A1 (en) | 1996-02-28 |
WO1994026130A1 (en) | 1994-11-24 |
US5422101A (en) | 1995-06-06 |
CA2162249A1 (en) | 1994-11-24 |
CN1124006A (zh) | 1996-06-05 |
DE69414704D1 (de) | 1998-12-24 |
AU689775B2 (en) | 1998-04-09 |
CA2162249C (en) | 1999-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1066930C (zh) | 用于降低胆固醇的混合饮料组合物 | |
DE60215156T3 (de) | Säurereguliertes viskoses ballaststoffsystem und seine verwendung | |
CN1082354C (zh) | 羟基柠檬酸浓缩物及制备方法 | |
Younes et al. | Effects of two fermentable carbohydrates (inulin and resistant starch) and their combination on calcium and magnesium balance in rats | |
US4689322A (en) | Pharmaceutical products, calcium mixed salts of polymeric, anionic carboxylic acids and/or their esters of sulfuric acid, and methods for their preparation and use | |
ES2940891T3 (es) | Composición de fibra dietética | |
PT1455605E (pt) | Substituto de bebidas gaseificadas | |
CN102264246A (zh) | 液体高脂肪蛋白组合物 | |
EP0630192B1 (en) | Psyllium drink mix compositions containing granulated base | |
CA2137904C (en) | Psyllium drink mix compositions | |
CA2137905C (en) | Psyllium drink mix compositions | |
PT91852B (pt) | Processo para a preparacao de produtos contendo psyllium | |
Boamah et al. | Physicochemical properties, biological properties and applications of gum tragacanth-A review | |
JPH03141226A (ja) | 食用酸を含有する凝集オオバコ包被 | |
DE69934046T2 (de) | Beta-glucooligosaccharide zur beschleunigung von calciumaufnahme | |
JP3380249B2 (ja) | オオバコドリンクミックス組成物 | |
CN1678205A (zh) | 含有纤维的水饮料 | |
JPH0564572A (ja) | イチヨウ葉抽出物入り清涼飲料 | |
EP0630194B1 (en) | Unflavored psyllium drink mix compositions | |
AU663693B2 (en) | Psyllium and cholestyramine compositions with improved palatability | |
US20240115494A1 (en) | Encapsulated compositions and method of use - affecting satiety | |
JPS6072817A (ja) | 鉄、亜鉛及びマグネシウムの代替物としての鉄(2価)塩、亜鉛塩、マグネシウム塩及びこれらの混合塩の改良 | |
ITRM990646A1 (it) | Integratore alimentare composto di biofenoli, calcio e fruttani (con o senza aggiunta di beta-glucani), da impiegare tal quale o come ingred |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |